ARTICLE | Company News
Sugen other research news
February 14, 1994 8:00 AM UTC
The Redwood City, Calif., company published evidence that blocking the action of vascular endothelial growth factor (VEGF) through its receptor, Flk-1, can check tumor growth in a mouse model for glioblastoma and other solid tumors.
In Nature, company scientists and colleagues in Germany used a retrovirus to deliver a mutant Flk-1, which clumped with the cells' own normal receptors, rendering them unable to receive the signal for blood vessel growth. Tumors implanted in mice then were unable to expand. ...